{
    "score": [
        0.8181818181818182
    ],
    "extracted": [
        0
    ],
    "abstract": [
        "sanofi to market new hemophilia drug in deal with alnylam ."
    ],
    "id": "714965.train",
    "article": [
        "stock markets3 hours ago . saved . see saved items . this article has already been saved in your saved items . paris , jan 8 - french pharmaceutical group sanofi sasy . pa said it has obtained the right to develop and sell a new hemophilia drug in a restructuring of its partnership with u. s. alnylam pharmaceuticals alny . o . under the agreement , sanofi will obtain global development and commercialization rights to fitusiran , currently in development for the treatment of people with hemophilia a and b. global commercialization of fitusiran will be done by sanofi genzyme , the specialty care global business unit of sanofi , while alnylam will receive royalties based on net sales of fitusiran products . ",
        "fitusiran complements sanofi genzyme 's rare hematology portfolio and will bring an innovative new treatment for people living with hemophilia , one of the most common rare diseases . alnylam will obtain global development and commercialization rights to a new treatment of attr amyloidosis , a rare disease caused by the build-up of an abnormal protein . `` the restructured alliance reflects sanofi genzyme 's sustained interest in the strong potential of alnylam 's portfolio of genetic medicines , '' said bill sibold , executive vice president and head of sanofi genzyme . sanofi said it will continue to have the right to opt into other alnylam rare genetic disease programs for development and commercialization in territories outside of the united states , canada and western europe , as well as one right to a global license . ",
        "disclaimer : fusion media would like to remind you that the data contained in this website is not necessarily real-time nor accurate . all cfds and forex prices are not provided by exchanges but rather by market makers , and so prices may not be accurate and may differ from the actual market price , meaning prices are indicative and not appropriate for trading purposes . therefore fusion media does n`t bear any responsibility for any trading losses you might incur as a result of using this data . fusion media or anyone involved with fusion media will not accept any liability for loss or damage as a result of reliance on the information including data , quotes , charts and buy/sell signals contained within this website . ",
        "please be fully informed regarding the risks and costs associated with trading the financial markets , it is one of the riskiest investment forms possible .   "
    ]
}